Want to see NTHI full AI Analyst Report?
NeOnc Technologies Holdings, Inc. (NTHI) AI Stock Analysis
Top Page
NeOnc Technologies Holdings, Inc.
(NASDAQ:NTHI)
The score is primarily weighed down by extremely weak financial performance (near-zero revenue, large and rising losses, heavy cash burn, and deeply negative equity) and a bearish technical trend (below major moving averages with negative MACD). Positive corporate developments in the clinical/regulatory pipeline and recent financing provide some support, but they do not outweigh the current financial strain and funding/dilution risk.
NeOnc Technologies Holdings, Inc. (NTHI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $93.91M
- Dividend Yield
- ―
- Average Volume (3M)
- 210.46K
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 1.57
- Revenue Growth
- -100.00%
- EPS Growth
- 18.94%
- Country
- US
- Employees
- 5
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model
Company Description
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in...
NeOnc Technologies Holdings, Inc. Financial Statement Overview
Summary
Financials reflect an early-stage, pre-revenue profile with severe operating weakness: revenue is effectively immaterial while net losses are very large and worsened sharply year-over-year. Cash flow is deeply negative with significant and increasing operating/free cash burn, and stockholders’ equity is deeply negative, increasing financing and dilution risk despite modest TTM debt and some asset growth.
Income Statement
4Very NegativeBalance Sheet
8Very NegativeCash Flow
6Very Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 39.99K | 83.00K | 70.46K | 20.00K | 0 |
| Gross Profit | -57.52K | 39.99K | 83.00K | 70.46K | 20.00K | 0 |
| EBITDA | -43.63M | -59.61M | -9.10M | -12.20M | -2.85M | -3.26M |
| Net Income | -47.20M | -62.15M | -11.90M | -14.92M | -3.05M | -3.38M |
Balance Sheet | ||||||
| Total Assets | 5.23M | 2.82M | 3.42M | 1.27M | 728.68K | 32.49K |
| Cash, Cash Equivalents and Short-Term Investments | 1.97M | 58.73K | 64.89K | 31.86K | 633.30K | 25.03K |
| Total Debt | 328.22K | 6.31M | 24.72K | 6.61M | 50.00K | 1.15M |
| Total Liabilities | 23.76M | 20.33M | 8.92M | 15.25M | 2.30M | 2.65M |
| Stockholders Equity | -18.53M | -17.51M | -5.50M | -13.99M | -1.58M | -2.62M |
Cash Flow | ||||||
| Free Cash Flow | -21.16M | -20.86M | -4.21M | -1.88M | -881.74K | -396.69K |
| Operating Cash Flow | -21.16M | -20.36M | -4.21M | -1.88M | -881.74K | -396.69K |
| Investing Cash Flow | 0 | -500.00K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 23.51M | 20.86M | 4.25M | 1.28M | 1.49M | 250.00K |
NeOnc Technologies Holdings, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTHI, the sentiment is Neutral. The current price of 3.26 is above the 20-day moving average (MA) of 2.86, below the 50-day MA of 3.48, and below the 200-day MA of 5.47, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 54.73 is Neutral, neither overbought nor oversold. The STOCH value of 47.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NTHI.
NeOnc Technologies Holdings, Inc. Risk Analysis
NeOnc Technologies Holdings, Inc. disclosed 83 risk factors in its most recent earnings report. NeOnc Technologies Holdings, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksNeOnc Technologies Holdings, Inc. Peers Comparison
Overall Rating
CLDI46Neutral- NTHI44Neutral
GTBP42Neutral
GOVX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| CLDI | 46Neutral | $2.53M | -0.01 | -372.86% | ― | ― | 53.95% |
| NTHI | 44Neutral | $93.91M | -1.47 | 309.09% | ― | -100.00% | 18.94% |
| GTBP | 42Neutral | $10.96M | -0.05 | -443.08% | ― | ― | 75.09% |
| GOVX | 39Underperform | $1.70M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NTHI | NeOnc Technologies Holdings, Inc. | 3.26 | -6.93 | -68.01% | |
| GOVX | Geovax Labs, Inc. | 0.17 | -14.18 | -98.83% | |
| GTBP | Gt Biopharma, Inc. | 5.32 | -10.26 | -65.85% | |
| CLDI | Calidi Biotherapeutics, Inc. | 0.69 | -23.79 | -97.19% |
NeOnc Technologies Holdings, Inc. Corporate Events
NeOnc Technologies Expands Abu Dhabi Oncology Collaboration Efforts
PositiveIn October 2026, NeOnc Technologies reported early clinical improvement in a critically ill three-year-old boy in Abu Dhabi with an aggressive brain tumor, treated with investigational intranasal NEO100 under its Compassionate Care program. The physi...
NeOnc Technologies boosts Gulf profile with Abu Dhabi summit
PositiveOn October 9, 2026, NeOnc Technologies Holdings, Inc. reported the resignation of Class I director Steven L. Giannotta, M.D., from its board, noting his departure did not stem from any dispute and that he will continue contributing on the companyR...
NeOnc Plans FDA End-of-Phase 1 Meeting for NEO212
PositiveNeOnc Technologies announced on September 28, 2026, that it is scheduled to meet in person with the U.S. Food and Drug Administration on November 17, 2026, for an End-of-Phase 1 Type B meeting regarding its investigational CNS cancer therapy NEO212....
NeOnc Simplifies Capital Structure Amid CNS Oncology Focus
PositiveNeOnc Technologies Holdings, Inc., a Nasdaq-listed, multi-Phase 2 clinical-stage biopharmaceutical company, is developing novel therapies for central nervous system cancers using its NEO platform to address blood-brain barrier challenges. Its lead ca...
NeOnc CEO Boosts Stake After Recent Offering
PositiveOn September 16, 2026, NeOnc Technologies Holdings reported that Executive Chairman, President and CEO Amir F. Heshmatpour bought an additional 35,000 shares of company stock on September 15 for about $115,400 at a weighted average price of roughly $...
NeOnc Technologies Announces $15 Million Registered Direct Offering
PositiveOn September 8 and 9, 2026, NeOnc Technologies Holdings, Inc. entered into definitive securities purchase and placement agency agreements for a registered direct offering with new and existing healthcare-focused institutional investors. The deal cove...
NeOnc Technologies Holds 2026 Annual Stockholder Meeting
PositiveNeOnc Technologies Holdings, Inc. held its 2026 annual meeting of stockholders via live webcast on August 14, 2026, with 77.92% of eligible common shares represented, establishing a quorum under its bylaws. Stockholders elected two Class I directors,...
NeOnc Announces Positive Phase 2a Data in Brain Cancer
PositiveOn August 12, 2026, NeOnc Technologies hosted an investor conference call to present top-line Phase 2a results from its NEO100-01 trial in recurrent IDH1-mutant high-grade glioma, reporting that the study met its primary endpoint with a median overal...
NeOnc Technologies Reports Positive Phase 2a Glioma Results
PositiveOn August 12, 2026, NeOnc Technologies reported positive topline Phase 2a results from its NEO100-01 study of intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, a setting with no approved targeted t...
NeOnc Highlights Q2 Results and CNS Oncology Progress
NeutralNeOnc reported its second-quarter 2026 results on August 10, 2026, alongside clinical and regulatory milestones for its NEO100 and NEO212 programs, underscoring a strategic focus on advancing central nervous system cancer treatments. The company comp...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026